Rigel Pharmaceuticals’ olutasidenib shows efficacy in published AML study

Rigel Pharmaceuticals announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating Rezlidhia – olutasidenib -, a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 or mIDH1, in patients with mIDH1 acute myeloid leukemia – AML – who were relapsed/refractory to prior venetoclax-based regimens. Olutasidenib alone or in combination with azacitidine demonstrated potential efficacy in patients with AML following failure of venetoclax combination therapy. Of the 18 patients with prior venetoclax treatment, 10 were relapsed, 6 were refractory, and 2 had complete remission with incomplete hematologic recovery to a venetoclax combination. Of the 16 R/R patients, 7 achieved a composite complete remission, 4 achieved complete remission, and 1 achieved CR with partial hematologic recovery. Both patients with CRi at study entry achieved CR. Red blood cell and platelet transfusion independence was achieved in 2/12 and 2/7 transfusion-dependent R/R patients at baseline, respectively. Safety was consistent with the overall profile of olutasidenib. The paper was published online in Leukemia & Lymphoma.